Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eltrombopag
Drug ID BADD_D00759
Description Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
Indications and Usage Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.
Marketing Status approved
ATC Code B02BX05
DrugBank ID DB06210
KEGG ID D03978
MeSH ID C520809
PubChem ID 135449332
TTD Drug ID D00PEH
NDC Product Code 47621-307
UNII S56D65XJ9G
Synonyms eltrombopag | Revolade | SB-497 115 | Promacta
Chemical Information
Molecular Formula C25H22N4O4
CAS Registry Number 496775-61-2
SMILES CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tooth loss12.01.17.026; 07.09.09.0010.000777%Not Available
Toothache07.09.06.0010.001280%
Transverse sinus thrombosis17.08.03.004; 24.01.04.0130.000229%Not Available
Trichorrhexis23.02.06.0070.000777%Not Available
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urinary tract infection20.08.02.001; 11.01.14.004--
Ventricular fibrillation02.03.04.0080.000229%
Vision blurred17.17.01.010; 06.02.06.0070.006127%
Visual impairment06.02.10.0130.004687%Not Available
Vitreous floaters06.09.01.0050.000777%
Vomiting07.01.07.003--
Mental status changes19.07.01.0010.003064%Not Available
Fibromyalgia15.05.02.0020.000777%Not Available
Hypoacusis04.02.01.0060.003910%
Peripheral swelling08.01.03.053; 02.05.04.0150.010540%Not Available
Brain death17.02.03.003; 08.04.01.0040.000229%Not Available
Osteopenia15.02.03.003; 14.04.04.0040.000503%Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Intervertebral disc protrusion15.10.01.0040.000617%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000892%
Deep vein thrombosis24.01.02.0030.002972%Not Available
Post transplant lymphoproliferative disorder16.21.02.004; 11.05.10.006; 01.13.02.0040.000229%Not Available
Cytokine release syndrome10.02.01.0100.000229%
Oesophageal rupture12.01.17.015; 07.04.05.0050.000229%Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.0010.000777%Not Available
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.0010.000229%Not Available
Blast cell crisis16.01.02.002; 01.10.02.0020.000229%Not Available
Transaminases increased13.03.04.036--Not Available
Haemorrhage24.07.01.0020.004847%Not Available
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages